Digestive Diseases

 

Vascular Involvement in Inflammatory Bowel Disease: Pathogenesis and Clinical Aspects

Papa A.a · Scaldaferri F.a · Danese S.b · Guglielmo S.a · Roberto I.a · Bonizzi M.a · Mocci G.a · Felice C.a · Ricci C.a · Andrisani G.a · Fedeli G.a · Gasbarrini G.a · Gasbarrini A.a

Author affiliations

aDepartment of Internal Medicine, Division of Gastroenterology, Catholic University of Rome, Rome, bIstituto Clinica Humanitas, Division of Gastroenterology, Rozzano (MI), Italy

Keywords: Inflammatory bowel diseaseCrohn’s diseaseUlcerative colitisCoagulationThrombosis

Related Articles for ""
Dig Dis 2008;26:149–155
https://doi.org/10.1159/000116773

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: April 21, 2008
Issue release date: April 2008

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: https://www.karger.com/DDI

Abstract

Crohn’s disease (CD) and ulcerative colitis (UC), the two major forms of inflammatory bowel disease (IBD), are chronic inflammatory conditions, characterized by a microvascular and also macrovascular involvement. Chronically inflamed intestinal microvessels of IBD patients have demonstrated significant alterations in their physiology and function compared with vessels from healthy and uninvolved IBD intestine. Recently, some studies have revealed that the poor mucosal healing, refractory inflammatory ulcerations and damage in the IBD intestine could depend on microvascular dysfunction, resulting in diminished vasodilatory capacity and tissue hypoperfusion in the IBD gut. Furthermore, several data show that the activation of intestinal endothelium plays a critical role in the pathogenesis and/or in perpetuating and amplifying the inflammatory process in IBD and, consequently, it is now emerging as a potential use of anticoagulant or coagulation-related drugs in treating IBD. IBD is also associated with an increased risk of macrovascular venous and arterial thrombosis. Thrombotic events occur prevalently as deep vein thrombosis and pulmonary embolism. They happen at an earlier age than in non-IBD patients. Prothrombotic risk factors in IBD patients could be distinguished as acquired, such as active inflammation, immobility, surgery, steroid therapy, and use of central venous catheters, and inherited. Furthermore, it has been found that IBD, per se, is an independent risk factor for thrombosis. The prevention of thromboembolic events in IBD patients includes the elimination of removable risk factors and, if thrombosis occurs, a pharmacological therapy similar to that used for thromboembolic events occurring in the general population.

© 2008 S. Karger AG, Basel



Related Articles:

References

  1. Fiocchi C: Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am J Physiol 1997;273:G769–G775.
    External Resources
  2. Hatoum OA, Miura H, Binion DG: The vascular contribution in the pathogenesis of inflammatory bowel disease. Am J Physiol 2003;285:H1791–H1796.
    External Resources
  3. Laroux FS, Grisham MB: Immunological basis of inflammatory bowel disease: role of the microcirculation. Microcirculation 2001;8:283–301.
    External Resources
  4. Ossama A, Hatoum OA, Binion DG: The vasculature and inflammatory bowel disease. Contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis 2005;11:304–313.
    External Resources
  5. Kirsner JB, Shorter RG: Inflammatory Bowel Disease. Baltimore, Williams & Wilkins, 1995.
  6. Arfors KE, Rutili G, Svensjo E: Microvascular transport of macromolecules in normal and inflammatory conditions. Acta Physiol Scand Suppl 1979;463:93–103.
    External Resources
  7. Granger DN, Kubes P: The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol 1994;55:662–675.
    External Resources
  8. Soriano A, Salas A, Salas A, Sans M, Gironella M, Elena M, Anderson DC, Pique JM, Panes J: VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest 2000;80:1541–1551.
    External Resources
  9. Hatoum OA, Binion DG, Otterson MF, et al: Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology 2003;125:58–69.
    External Resources
  10. Wakefield AJ, Sankey EA, Dhillon AP, et al: Granulomatous vasculitis in Crohn’s disease. Gastroenterology 1991;100:1279–1287.
    External Resources
  11. Dvorak AM, Monahan RA, Osage JE, et al: Crohn’s disease: transmission electron microscopic studies. II. Immunologic inflammatory response. Alterations of mast cells, basophils, eosinophils, and the microvasculature. Hum Pathol 1980;11:606–619.
    External Resources
  12. Podolsky DK, Lobb R, King N, et al: Attenuation of colitis in the cottontop tamarin by anti-α4 integrin monoclonal antibody. J Clin Invest 1993;92:372–380.
    External Resources
  13. Briskin M, Winsor-Hines D, Shyjan A, et al: Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151:97–110.
    External Resources
  14. Binion DG, West GA, Volk EE, et al: Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 1998;352:1742–1746.
    External Resources
  15. Talbot RW, Heppell J, Dozois RR, et al: Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986;61:140–145.
    External Resources
  16. Sloan WP Jr, Bargen JA, Gage RB: Life histories of patients with chronic ulcerative colitis: a review of 2,000 cases. Gastroenterology 1968;54(suppl):819–822.
  17. Graef V, Baggenstoss AH, Sauer WG, et al: Venous thrombosis occurring in non-specific ulcerative colitis. A necropsy study. Arch Intern Med 1966;117:377–382.
    External Resources
  18. Bernestein CN, Blanchard JF, Houston DS, et al: The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001;85:430–434.
    External Resources
  19. Grip O, Svensson PJ, Lindgren S: Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol 2000;35:619–623.
    External Resources
  20. Thompson NP, Wakefield AJ, Pounder RE: Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 1995;108:1011–1015.
    External Resources
  21. Papa A, Danese S, Gasbarrini A, et al: Potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:1403–1409.
    External Resources
  22. Papa A, Danese S, Grillo A, Gasbarrini G, Gasbarrini A: Inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol 2003;98:1247–1251.
    External Resources
  23. Linderberg E, Jurnerot G, Huitfeldt B: Smoking in Crohn’s disease: effect on localization and clinical course. Gut 1992;33:779–782.
    External Resources
  24. Godet PG, May GR, Sutherland LR: Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease. Gut 1995;108:1011–1015.
  25. Papa A, De Stefano V, Danese S, Gasbarrini A, Gasbarrini G: Thrombotic complications in inflammatory bowel disease: a multifactorial etiology. Am J Gastroenterol 2001;96:1301–1302.
    External Resources
  26. Oldenburg B, Van Tuyl BA, van der Griend R, Fijnheer R, van Berge Henegouwen GP: Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. Dig Dis Sci 2005;50:235–240.
    External Resources
  27. Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, Grisar J, Machold K, Scholz S, Vogelsang H, Novacek G: Is inflammatory bowel disease an independent and disease-specific risk factor for thromboembolism? Gut 2004;53:542–548.
    External Resources
  28. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ: Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004;99:97–101.
    External Resources
  29. Johns DR: Cerebrovascular complications of inflammatory bowel disease. Am J Gastroenterol 1991;86:367–370.
    External Resources
  30. Maccini DM, Berg JC, Bell GA: Budd-Chiari syndrome and Crohn’s disease. An unreported association. Dig Dis Sci 1989;34:1933–1936.
    External Resources
  31. Keyser BJ, Hass AN: Retinal vascular disease in ulcerative colitis. Am J Ophthalmol 1994;118:395–396.
    External Resources
  32. Hatoum OA, Spinelli KS, Abu-Hajir M, et al: Mesenteric venous thrombosis in inflammatory bowel disease. J Clin Gastroenterol 2005;39:27–31.
    External Resources
  33. Umit H, Asil T, Celik Y, et al: Cerebral sinus thrombosis in patients with inflammatory bowel disease: a case report. World J Gastroenterol 2005;11:5404–5407.
    External Resources
  34. Schneiderman JH, Sharpe JA, Sutton DM: Cerebral and retinal vascular complications of inflammatory bowel disease. Ann Neurol 1979;5:331–337.
    External Resources
  35. Younes-Mhenni S, Derex L, Berruyer M, et al: Large-artery stroke in a young patient with Crohn’s disease. Role of vitamin B6 deficiency-induced hyperhomocysteinemia. J Neurol Sci 2004;221:113–115.
    External Resources
  36. Levy PJ, Tabares AH, Olin JW: Lower extremity arterial occlusions in young patients with Crohn’s colitis and premature atherosclerosis: report of six cases. Am J Gastroenterol 1997;92:494–497.
    External Resources
  37. Novotny DA, Rubin RJ, Slezak FA, Porter JA: Arterial thromboembolic complications of inflammatory bowel disease. Report of three cases. Dis Colon Rectum 1992;35:193–196.
    External Resources
  38. Ashkan K, Nasim A, Sayers RD, Dennis MJ: Arterial thrombosis: a complication of loop ileostomy. Eur J Gastroenterol Hepatol 1998;10:795–796.
    External Resources
  39. Efremidis M, Prappa E, Kardaras F: Acute myocardial infarction in a young patient during an exacerbation of ulcerative colitis. Int J Cardiol 1999;70:211–212.
    External Resources
  40. Mutlu B, Ermeydan CM, Enc F, et al: Acute myocardial infarction in a young woman with severe ulcerative colitis. Int J Cardiol 2002;83:183–185.
    External Resources
  41. Szychta P, Reix T, Sevestre MA, Brazier F, Pietri J: Aortic thrombosis and ulcerative colitis. Ann Vasc Surg 2001;15:402–404.
    External Resources
  42. Novacek G, Haumer M, Schima W, et al: Aortic mural thrombi in patients with inflammatory bowel disease: report of two cases and review of the literature. Inflamm Bowel Dis 2004;10:430–435.
    External Resources
  43. Papa A, Santoliquido A, Danese S, et al: Increased carotid intima-media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005;22:839–846.
    External Resources
  44. Carty E, MacEy M, Rampton DS: Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:1169–1179.
    External Resources
  45. Thomas G, Skrinska VA, Lucas FV: The influence of glutathione and other thiols on human platelet aggregation. Thromb Res 1986;44:859–866.
    External Resources
  46. Hommes DW, van Dullemen HM, Levi M, et al: Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn’s disease. Haemostasis 1997;27:269–277.
    External Resources
  47. Danese S, Sans M, Scaldaferri F, et al: TNF-alpha blockade downregulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn’s disease. J Immunol 2006;176:2617–2624.
    External Resources
  48. Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, Gasbarrini G, Gasbarrini A: Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005;11:7227–7236.
    External Resources
  49. Koutroubakis IE: Therapy insight: vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005;2:266–272.
    External Resources
  50. Carty E, Rampton DS, Schneider H, Rutgeerts P, Wright JP: Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn’s disease. Aliment Pharmacol Ther 2001;15:1323–1329.
    External Resources
  51. Tytgat GN, Van Nueten L, Van De Velde I, Joslyn A, Hanauer SB: Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment Pharmacol Ther 2002;16:87–99.
    External Resources
  52. Patscheke H: Thromboxane A2/prostaglandin H2 receptor antagonists. A new therapeutic principle. Stroke 1990;21(suppl):139–142.
  53. Panes J, Esteve M, Cabre E, et al: Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology 2000;119:903–908.
    External Resources
  54. Saibeni S, Spina L, Signorelli C, et al: Safety and efficacy of oral, colonic-release, low-molecular-weight heparin-MMx™ for the treatment of mild to moderate left-sided ulcerative colitis: preliminary report of a pilot study. Gut 2006;55(suppl 5):A129.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: April 21, 2008
Issue release date: April 2008

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: https://www.karger.com/DDI

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2008, Vol.26, No. 2

April 2008

Article

Recommend This
TOP